Država: Združene države Amerike
Jezik: angleščina
Source: NLM (National Library of Medicine)
FLUORESCEIN SODIUM (UNII: 93X55PE38X) (FLUORESCEIN - UNII:TPY09G7XIR)
A-S Medication Solutions
INTRAVENOUS
PRESCRIPTION DRUG
AK-FLUOR® 10% (100 mg/mL) and 25% (250 mg/mL) is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. AK-FLUOR® is contraindicated in patients with known hypersensitivity to fluorescein sodium or any other ingredients in this product. Rare cases of death due to anaphylaxis have been reported [see Warnings and Precautions (5.1) and Adverse Reactions (6.2) ]. Pregnancy Category C. Adequate animal reproduction studies have not been conducted with fluorescein sodium. It is also not known whether fluorescein sodium can cause fetal harm when administered to a pregnant woman. Fluorescein sodium should be given to a pregnant woman only if clearly needed. Fluorescein sodium has been demonstrated to be excreted in human milk. Caution should be exercised when fluorescein sodium is administered to a nursing woman. Pediatric patients have been included in clinical studies. No overall differences in safety or effectiveness have been observed between pediatric and adult patient
Product: 50090-4535 NDC: 50090-4535-0 5 mL in a VIAL, SINGLE-DOSE
New Drug Application
AK-FLUOR- FLUORESCEIN SODIUM INJECTION A-S MEDICATION SOLUTIONS ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE AK-FLUOR 10% AND AK- FLUOR 25% SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR THE PRODUCTS IN AK- FLUOR 10% AND AK-FLUOR 25%. AK-FLUOR (FLUORESCEIN INJECTION, USP) 10% AND AK-FLUOR (FLUORESCEIN INJECTION, USP) 25% INTRAVENOUS INJECTION INITIAL U.S. APPROVAL: 1976 INDICATIONS AND USAGE AK-FLUOR is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. (1) DOSAGE AND ADMINISTRATION The normal adult dose of AK-FLUOR 10% is 5 mL (500 mg) and of AK-FLUOR 25% is 2 mL (500 mg) via intravenous administration. (2.1) For children, the dose should be calculated on the basis of 35 mg for each ten pounds of body weight (7.7 mg/kg body weight). (2.2) Do not mix or dilute with other solutions or drugs. (2.2) DOSAGE FORMS AND STRENGTHS AK-FLUOR (fluorescein injection, USP) 10%, 100 mg/mL in a 5 mL single dose vial (3) AK-FLUOR (fluorescein injection, USP) 25%, 250 mg/mL in a 2 mL single dose vial (3) CONTRAINDICATIONS Hypersensitivity to any component of this product. (4.1) WARNINGS AND PRECAUTIONS Respiratory reactions.(5.1) Severe local tissue damage. (5.2) ADVERSE REACTIONS The most common adverse reactions include skin discoloration, urine discoloration, nausea, vomiting, and gastrointestinal distress. (6) TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT AKORN AT 1-800-932-5676 OR FDA AT 1- 800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH (6) USE IN SPECIFIC POPULATIONS Caution should be exercised when fluorescein sodium is administered to a nursing woman. (8.3) SEE 17 FOR PATIENT COUNSELING INFORMATION. REVISED: 4/2021 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Dosing 2.2 Preparation for Administration 2.3 Administration 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS ® ® ® ® ® ® ® ® ® ® ® 4.1 Hypersensitivity 5 WARNINGS AND PRECAUTIONS 5.1 R Preberite celoten dokument